Recursion Pharmaceuticals Inc
RXRX5.030USD
-0.370-6.85%
Cierre 06/27, 16:00（ET）Cotizaciones retrasadas 15 min
2.04BCap. mercado
PérdidaP/E TTM
Más Datos de Recursion Pharmaceuticals Inc Compañía
Recursion Pharmaceuticals, Inc. is a clinical stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology include REC-617, REC-1245, REC-3565 and REC-4539. Its clinical programs in rare diseases include REC-994, REC-4881, REC-2282, and REC-3964. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors.
Información de la empresa
Símbolo de cotizaciónRXRX
Nombre de la empresaRecursion Pharmaceuticals Inc
Fecha de salida a bolsaApr 16, 2021
Fundada en2013
Director ejecutivoDr. Christopher Gibson, Ph.D.
Número de empleados840
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 16
Dirección41S Rio Grande Street
CiudadSALT LAKE CITY
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal84101
Teléfono13852690203
Sitio Webhttps://www.recursion.com/
Símbolo de cotizaciónRXRX
Fecha de salida a bolsaApr 16, 2021
Fundada en2013
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.19M
+0.69%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
166.43K
-4.07%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
142.54K
-20.25%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
132.89K
+19.86%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
91.71K
+31.59%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+30.12%
Dr. Najat Khan, Ph.D.
Dr. Najat Khan, Ph.D.
Director, Chief Research and Development Officer, Chief Commercial Officer
Director, Chief Research and Development Officer, Chief Commercial Officer
14.63K
-20.60%
Mr. Zachary Bogue, J.D.
Mr. Zachary Bogue, J.D.
Independent Director
Independent Director
9.38K
--
Dr. Franziska Michor, Ph.D.
Dr. Franziska Michor, Ph.D.
Independent Director
Independent Director
--
--
Dr. Blake Borgeson, Ph.D.
Dr. Blake Borgeson, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.19M
+0.69%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
166.43K
-4.07%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
142.54K
-20.25%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
132.89K
+19.86%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
91.71K
+31.59%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+30.12%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 28 de may
Actualizado: mié., 28 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
ARK Investment Management LLC
8.71%
The Vanguard Group, Inc.
8.06%
Baillie Gifford & Co.
6.10%
BlackRock Institutional Trust Company, N.A.
5.02%
SB Global Advisers Ltd
3.67%
Other
68.43%
Accionistas
Accionistas
Proporción
ARK Investment Management LLC
8.71%
The Vanguard Group, Inc.
8.06%
Baillie Gifford & Co.
6.10%
BlackRock Institutional Trust Company, N.A.
5.02%
SB Global Advisers Ltd
3.67%
Other
68.43%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
36.58%
Investment Advisor/Hedge Fund
19.62%
Venture Capital
8.74%
Sovereign Wealth Fund
4.12%
Individual Investor
3.17%
Research Firm
2.16%
Hedge Fund
2.01%
Corporation
1.93%
Bank and Trust
0.86%
Other
20.83%
Participación institucional
Actualizado: mar., 4 de mar
Actualizado: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
637
324.02M
81.93%
+29.39M
2024Q4
611
317.29M
80.77%
+25.35M
2024Q3
560
281.65M
104.01%
-6.72M
2024Q2
527
272.94M
105.41%
+14.66M
2024Q1
478
234.97M
104.72%
-10.28M
2023Q4
433
227.80M
110.74%
+18.50M
2023Q3
402
195.18M
97.47%
+1.19M
2023Q2
358
172.49M
89.73%
-20.74M
2023Q1
345
171.25M
93.19%
-16.02M
2022Q4
321
167.85M
92.66%
-946.19K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
ARK Investment Management LLC
32.35M
8.19%
-422.79K
-1.29%
Dec 31, 2024
The Vanguard Group, Inc.
33.97M
8.6%
+9.74M
+40.18%
Dec 31, 2024
Baillie Gifford & Co.
24.86M
6.29%
-375.81K
-1.49%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
20.31M
5.14%
+2.56M
+14.39%
Dec 31, 2024
SB Global Advisers Ltd
14.67M
3.71%
+14.67M
--
Dec 31, 2024
Kinnevik AB
11.91M
3.01%
--
--
Dec 31, 2024
State Street Global Advisors (US)
12.58M
3.18%
-291.91K
-2.27%
Dec 31, 2024
Mubadala Investment Company PJSC
12.99M
3.29%
--
--
Dec 31, 2024
DCVC Management Co, LLC
5.94M
1.5%
-3.73M
-38.55%
Dec 31, 2024
Novo Holdings A/S
10.11M
2.56%
+10.11M
--
Dec 31, 2024
Ver más
ETFs relacionados
Actualizado: vie., 6 de jun
Actualizado: vie., 6 de jun
Nombre
Proporción
ARK Genomic Revolution ETF
4.95%
ARK Innovation ETF
1.5%
First Trust Nasdaq AI and Robotics ETF
1.01%
AXS Green Alpha ETF
0.81%
Franklin Genomic Advancements ETF
0.66%
WisdomTree BioRevolution Fund
0.64%
Main Thematic Innovation ETF
0.59%
SPDR S&P Biotech ETF
0.56%
Virtus LifeSci Biotech Clinical Trials ETF
0.45%
Direxion Daily S&P Biotech Bull 3X Shares
0.37%
Ver más
ARK Genomic Revolution ETF
Proporción4.95%
ARK Innovation ETF
Proporción1.5%
First Trust Nasdaq AI and Robotics ETF
Proporción1.01%
AXS Green Alpha ETF
Proporción0.81%
Franklin Genomic Advancements ETF
Proporción0.66%
WisdomTree BioRevolution Fund
Proporción0.64%
Main Thematic Innovation ETF
Proporción0.59%
SPDR S&P Biotech ETF
Proporción0.56%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.45%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.37%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
